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ABSTRACT  
Monoclonal gammopathy of undetermined significance (MGUS) is a common condition in the 
elderly. A number of studies have investigated the relationship between MGUS and bone health 
outcomes including bone mineral density (BMD), osteoporosis and fractures, but no meta-analysis 
exists. We conducted a systematic review and exploratory meta-analysis comparing bone health 
outcomes in patients with MGUS.  
Two independent authors searched PubMed and Scopus from inception until October 19, 2016. A 
meta-analysis of cross-sectional and longitudinal studies investigating fractures and BMD was 
conducted.  Standardized mean differences (SMD) ± 95% and confidence intervals (CIs) were 
calculated for BMD, and risk ratios (RRs) were calculated for prevalent and incident fractures. Of 
174 initial hits, 10 studies of moderate methodological quality were eligible, including 8,711 
individuals with MGUS vs. 52,865 controls. Compared to controls, subjects with MGUS showed 
significantly lower values for radial cortical volumetric BMD (1 study; SMD=-5.45, 95%CI: -7.24 to 
-3.66), but not at the lumbar spine, femoral neck or hip. The incidence of fractures was higher in 
people with MGUS (n=7,466) versus controls (n=52,304) (RR=1.36, 95% CI: 1.28-1.44, I2=0%) over 
a median of 12.5 year follow up.  The incidence of vertebral fractures was particularly elevated 
(RR=2.50, 95%CI: 1.53-4.06) although limited to two studies. 
In conclusion, although with limitations, our preliminary meta-analysis suggests that patients with 
MGUS are at higher risk of fractures despite evidence for differences in BMD being equivocal.  
Future longitudinal research is required to confirm our findings and determine if fracture prevention 
interventions are warranted in people with MGUS.   
 
Keywords: Monoclonal gammopathy of undetermined significance; osteoporosis; fractures; aging. 
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INTRODUCTION 
Monoclonal gammopathy of undetermined significance (MGUS) (defined by a serum monoclonal 
protein level of <3.0 g/dL, <10% bone marrow plasma cells, and the absence of plasma cell 
proliferation‐related complications) is a common condition[1], especially in the elderly in which 
reaches a prevalence of about 8% in those older than 85 years.[2] Approximately 1% of people 
affected by MGUS progress to a diagnosis of multiple myeloma (MM) every year.[2]   
Whilst the majority of research to date has considered the progression from MGUS to MM, recent 
research has also demonstrated that MGUS appears to be associated with bone health outcomes, and 
in particular osteoporosis and fractures.[3] Reasons for this relationship include the fact that MGUS 
seems to be associated with an uncoupling in osteoclasts (increased) and osteoblasts (decreased) 
balance and a higher production of pro-inflammatory and bone reabsorptive cytokines thus increasing 
the probability of osteoporosis and fractures.[3, 4]  
However, the literature considering MGUS and bone health outcomes is equivocal and no quantitative 
synthesis exists. Therefore, we conducted a systematic review and exploratory meta-analysis 
investigating the association between MGUS and osteoporosis, bone mineral density (BMD) and 
fractures risk. We hypothesized that people with MGUS are at increased risk of poor bone health 
outcomes.  
      
METHODS 
This systematic review was conducted following the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA) statement.[5] 
 
Search Strategy 
Two investigators (NV and CL) independently and blinded of the other investigator’s decision 
searched PubMed and Scopus, without language restriction, from database inception until 10/19/16, 
for studies comparing the presence of fractures and BMD values between patients with MGUS vs. 
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controls. Any inconsistencies were resolved by consensus with a third author (BS) available for 
mediation. In PubMed, we used the following search strategy: (“Monoclonal Gammopathy” OR 
“MGUS”) AND ("bone mineral density" OR “bone density” OR “BMD” OR "fracture*" OR 
"osteoporosis" OR “dxa” OR “Absorptiometry, X-Ray”). In Scopus the search used was: “TITLE-
ABS-KEY ( "Monoclonal Gammopathy"  OR  "MGUS" )  AND  TITLE-ABS-KEY ( "bone mineral 
density"  OR  "bone density"  OR  "BMD"  OR  "fracture*"  OR  "osteoporosis"  OR  "dxa"  OR  
"Absorptiometry, X-Ray" )”. Reference lists of included articles and those relevant to the topic were 
hand-searched for identification of additional, potentially relevant articles. 
 
Study Selection 
We included cross-sectional and/ or longitudinal studies comparing data on osteoporosis, fractures, 
BMD, and T-scores (deviation from the bone mass of an average healthy 30 year old adult)[6] 
between patients with MGUS vs. controls. Data about bone outcomes in patients with MGUS were 
summarized as prevalence. In case of doubled study, the most recent was selected. Specific inclusion 
criteria were: (1) reported BMD values or fractures, (2) validated diagnosis of MGUS and (3) 
published in a peer-review journal. Studies were excluded if they (1) measured only in vitro 
parameters (e.g. bone cellular markers) or used animal models or (2) reported only laboratory data 
(i.e. serum laboratory markers of bone deposition or reabsorption). The corresponding author was 
contacted at least two times in a month for additional information, if needed.  
 
Data Extraction 
Two authors (GS, EM) independently extracted data using a standardized spreadsheet. Any 
disagreement was resolved by consensus. The following information were extracted: i) study 
population characteristics, ii) duration of follow-up (for longitudinal studies), iii) clinical setting in 
which the study was performed, iv) percentage of IgG monoclonal band, v) main characteristics of 
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MGUS and control groups (age, percentage of women and body mass index), vi) matching variables 
used, and vi) quality scores.  
 
Quality assessment 
The Newcastle Ottawa Scale (NOS) was used to assess the quality of included studies. [7] However 
the item  “demonstration that outcome of interest was not present at start of study”  was omitted as 
it is not appropriate.   
 
Statistical Analysis 
The primary outcomes were the prevalence or incidence of fractures and characteristics of BMD 
parameters, comparing those with MGUS vs. controls. When combining studies, the random effects 
model was used to account for study heterogeneity.[8] For BMD data, standardized mean difference 
(SMD) with its 95% confidence interval (CI) was used, as well as risk ratios (RRs) for prevalent or 
incident fractures.  
Study heterogeneity was measured using the chi-squared and I-squared statistics, with chi-squared 
p<0.05 and I-squared ≥50% indicating the presence of significant heterogeneity.[9] We anticipated 
conducting meta-regression analysis for outcomes including ≥4 studies. The meta-analysis was 
performed using Comprehensive Meta-Analysis V3. 
 
RESULTS 
 
The search identified 184 non duplicate potentially eligible studies. After excluding 164 papers 
through title and abstract review and 10 from full text examination, 10 studies[10–19] were included 
(Supplementary Figure 1).  
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Study and Patient Characteristics 
Studies and patient characteristics are summarized in Supplementary Table 1 (cross-sectional) and 
2 (longitudinal). The 9 analyzed studies included a total of 8,711 participants with MGUS (mainly 
with an IgG component) vs. 52,865 controls. The mean age of those with MGUS was 70 (range 61.3-
73.5) and 54% females.   
All of the studies comparing MGUS vs. control group were matched for age and and/ or sex. The 
majority of the studies were made in Europe or in North America. Cross-sectional surveys were 
predominantly conducted among outpatients, while longitudinal included only community-dwellers. 
 
Methodological quality of included studies 
The quality of the studies was good, since among 8 points possible available, the median for cross-
sectional and longitudinal studies  was 5 and 7, respectively (Supplementary Tables 1-3). 
 
Cross-sectional bone health outcomes 
Four studies [12–15] reported an overall prevalence of fractures of 14% (95%CI: 3-52) in MGUS 
participants, while the prevalence of osteoporosis in 3 studies[12, 13, 19] was 14% (95%CI:2-62) 
(Supplementary Figures 1-2).  
As reported in Table 1, BMD (lumbar spine, hip and femoral neck) and T-scores (lumbar spine and 
hip) were not different between MGUS and controls. Regarding pQCT findings, one study[11] 
reported that MGUS patients had significantly lower radial cortical volumetric BMD than controls 
(SMD=-5.45, 95%CI: -7.24 to -3.66). Data from another study[12] demonstrated that MGUS patients 
had a significantly higher prevalence of total (RR=2.51, 95%CI: 1.89-3.33) and vertebral fractures 
(RR=2.30, 95%CI: 1.71-3.11) (Table 2).   
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Longitudinal studies and incidence of fractures 
Over a median follow up period of 12.5 years, data were pooled across three studies [16–18] among 
7,466 people with MGUS and 52,304 controls, demonstrating a significant higher incidence of 
fractures versus controls (RR=1.36, 95% CI: 1.28-1.44, I2=0%). The risk of vertebral fractures was 
particularly elevated among 5,931 people with MGUS and 36,594 controls (2 studies[16, 17]; 
RR=2.50, 95%CI: 1.53-4.06, I2=80%). 
 
DISCUSSION 
To the best of our knowledge this is the first systematic review and meta-analysis investigating the 
relationship between MGUS and bone health outcomes.  
Despite the limited number of studies included, our data suggests that people with MGUS have a 
higher prevalence and incidence of fractures (particularly vertebral) and lower cortical BMD, while 
the BMD (assessed with DXA) seems not to be affected by this pathological condition. A possible 
explanation of this finding is that patients with MGUS have some effect of degenerative changes 
(particularly vertebral wedging/compressions) that are well-known pitfalls in the correct 
interpretation of  DXA results. Another possible explanation is that DXA is not able to measure 
microarchitectural changes (like cortical porosity) at central sites as observed in the HRpQCT studies 
at peripheral site (like radius). Therefore, our findings suggest that the BMD measurements with DXA 
might not be reliable in people with MGUS.  
Over a median follow-up of 12.5 years including almost 60,000 people, we found that patients with 
MGUS are at 36% and over double the risk of any and vertebral fractures. The reasons for this 
increased risk of fractures among people with MGUS are yet to be elucidated. However, one possible 
reason is that among patients with MGUS, the reduction in cortical BMD observed is not 
counterbalanced by an increase in trabecular component, thus providing only a partial biomechanical 
adaptation to limit the overall loss of bone strength.[20] Another potential hypothesis for the increased 
fracture rate among people with MGUS is that a significant percentage develop a multiple myeloma 
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during follow-up period and it is well-known that patients with this condition have a high presence 
of pathological fractures.[21] It seems that patients with MGUS and multiple myeloma share some 
common pathways that could increase osteoclasts [3] [e.g. receptor activator for NF‐kB ligand 
(RANKL), chemokine (C‐C) ligand motif 3 (CCL3)/macrophage inflammatory protein (MIP)‐1a] 
and decreasing osteoblasts activity [3] [e.g. Wnt signalling antagonists Dickkopf‐related protein 1 
(DKK1), soluble frizzled related proteins 2 and 3, and sclerostin]. Whilst this might possibly explain 
our results, the clinical impact of these alterations seem to be contradictory, since Drake observed 
that some studies reported significant differences in bone turnover in MGUS compared to controls, 
while another study did not.[3] Therefore, clearly future research is needed to disentangle these 
relationships and confirm the increased incidence of fractures in MGUS patients, whilst also 
attempting to disentangle potential reasons for this.   
The findings of our meta-analysis should be interpreted within its clear limitations. The main is the 
small number of studies within each outcome. This not only means that our results should be 
considered preliminary, but this also precluded us from investigating publication bias. Of particular 
importance is that publication bias is a very common problem due to the presence of studies reporting 
significant positive associations [22], that we unable to address due to the limited number of the 
studies available for each outcome. Thus, we think that this factor could play a role in the 
interpretation of our results Second, within the longitudinal studies, it remains unclear how many 
people with MGUS developed multiple myeloma, which could be of importance to differentiate 
osteoporotic and pathological fractures. Third, the assessment of potential confounders (like age, 
medications and renal function) is limited to a single study and might influence fracture rates in people 
with MGUS. Finally, although we identified a high heterogeneity for several outcomes, we were not 
able to run any meta-regression analysis for identifying potential moderators due to the limited 
number of studies for each outcome. Among the strengths of our work we could consider the fact that 
it is the first meta-analysis assessing the impact of MGUS on bone health outcomes and the large 
number of the participants included.  
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In conclusion, from our preliminary meta-analysis, it appears that patients with MGUS are at higher 
risk of future fractures despite evidence for differences in BMD being less apparent.  Future research 
is required to build on our results. In clinical practice, people with MGUS might benefit from 
interventions to prevent osteoporosis and fractures.    
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